{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:49:26Z","timestamp":1790495366804,"version":"4.1.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"name":"Centre Hospitalier R\u00e9gional d'Orl\u00e9ans"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1093\/jac\/dkv430","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T20:53:40Z","timestamp":1451336020000},"page":"1046-1050","source":"Crossref","is-referenced-by-count":61,"title":["Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients"],"prefix":"10.1093","volume":"71","author":[{"given":"Camelia","family":"Gubavu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Prazuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamadou","family":"Niang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Buret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Guinard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Avettand-F\u00e8no\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,27]]},"reference":[{"key":"2016031409382550000_71.4.1046.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8722"},{"key":"2016031409382550000_71.4.1046.2","unstructured":"Prise en Charge M\u00e9dicale des Personnes Vivant avec le VIH. Recommandations du Groupe d'Experts. Rapport 2013 . http:\/\/www.sante.gouv.fr\/IMG\/pdf\/Rapport_Morlat_2013_Mise_en_ligne.pdf ."},{"key":"2016031409382550000_71.4.1046.3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir626"},{"key":"2016031409382550000_71.4.1046.4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0361-6"},{"key":"2016031409382550000_71.4.1046.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00097-3"},{"key":"2016031409382550000_71.4.1046.6","doi-asserted-by":"crossref","first-page":"19788","DOI":"10.7448\/IAS.17.4.19788","article-title":"Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials","volume":"17","author":"Arribas","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2016031409382550000_71.4.1046.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60084-2"},{"key":"2016031409382550000_71.4.1046.8","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1084"},{"key":"2016031409382550000_71.4.1046.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"2016031409382550000_71.4.1046.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku535"},{"key":"2016031409382550000_71.4.1046.11","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834a1dd9"},{"key":"2016031409382550000_71.4.1046.12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"2016031409382550000_71.4.1046.13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fphar.2015.00090","article-title":"Will drug resistance against dolutegravir in initial therapy ever occur?","volume":"6","author":"Wainberg","year":"2015","journal-title":"Front Pharmacol"},{"key":"2016031409382550000_71.4.1046.14","unstructured":"Rojas J , Blanco JL , Lonca M et al . Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression: a 24-week pilot study. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, 2015. Abstract LBPS4\/2. European AIDS Clinical Society, Brussels, Belgium."},{"key":"2016031409382550000_71.4.1046.15","unstructured":"Katlama C , Souli\u00e9 C , Blanc C et al . Dolutegravir monotherapy in HIV-infected patients with suppressed HIV viremia. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, 2015. Abstract PS4\/4. European AIDS Clinical Society, Brussels, Belgium."},{"key":"2016031409382550000_71.4.1046.16","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000187"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/71\/4\/1046\/6993056\/dkv430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T10:07:46Z","timestamp":1503569266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkv430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,27]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,3,14]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1093\/jac\/dkv430"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv430","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,27]]}}}